Fractyl Cuts 45% of Staff, Ends Rejuva Development to Fund Revita FDA Push
GUTS is trading near its 52-week low of $1.11 (3.6% above the low) on elevated volume (2.4× avg).
Summary
Fractyl is cutting about 45% of its workforce, taking roughly $2 million in severance charges, and discontinuing internal Rejuva development to focus cash on Revita's planned late-Q4 2026 FDA De Novo submission. Runway is extended into Q2 2027 with quarterly cash burn expected to fall to about $8 million.
Key Events · Legal and Risk Events · GUTS
-
45% Workforce Reduction Adopted
The board adopted a plan on October 21, 2026 to cut approximately 45% of headcount, with the reduction expected to be substantially completed by November 2026.
-
~$2M Severance Charge Expected
Fractyl estimates roughly $2 million in severance and termination costs, the majority to be incurred in Q4 2026; additional charges such as impairments are possible.
-
Rejuva Program Discontinued
Internal development of the Rejuva gene therapy program stops, and the company is seeking strategic alternatives for it with no assurance a transaction results.
-
Runway Extended Into Q2 2027
Existing cash is expected to fund operations into Q2 2027, with quarterly operating cash burn cut about 50% to approximately $8 million by the end of Q2 2027.
Analysis · GUTS · Industrial Applications And Services
Fractyl is betting the company on Revita. To concentrate cash on a planned FDA De Novo submission in late Q4 2026 and 12-month REMAIN-1 data in Q1 2027, it is cutting roughly 45% of its workforce, taking about $2 million in severance charges, and shutting internal development of the Rejuva gene therapy program. Management says the moves stretch runway into Q2 2027 and halve quarterly operating cash burn to roughly $8 million by then — a thin cushion for a company that previously disclosed a going concern warning and a Nasdaq delisting notice. The executive change is notable: co-founder President and Chief Product Officer Jay Caplan retires October 30, 2026, with CEO Harith Rajagopalan adding the President title. The upside case now rests almost entirely on Revita's regulatory path; any delay in the De Novo submission or a weak 12-month readout would leave little room.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.8% of the 1026 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GUTS was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $1.11 to $29.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.